Moving towards efficient therapies in type 1 diabetes: to combine or not to combine?

[1]  J. Bluestone,et al.  Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. , 2006, The Journal of clinical investigation.

[2]  Pau Serra,et al.  Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice , 2006, Nature Immunology.

[3]  M. V. von Herrath,et al.  Lost in translation , 2005, The Journal of experimental medicine.

[4]  G. Nepom,et al.  Targeting T Lymphocytes for Immune Monitoring and Intervention in Autoimmune Diabetes , 2005, American journal of therapeutics.

[5]  B. Bisikirska,et al.  TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. , 2005, The Journal of clinical investigation.

[6]  M. Vonherrath.  E1-INT (Transition Therapeutics/Novo Nordisk). , 2005 .

[7]  W. Suarez-Pinzon,et al.  Combination therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses hyperglycemia in diabetic NOD mice. , 2005, Diabetes.

[8]  Å. Lernmark,et al.  Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. , 2005, Journal of diabetes and its complications.

[9]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[10]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[11]  J. Lakey,et al.  Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet {beta}-cells from pancreatic duct cells and an increase in functional {beta}-cell mass. , 2005, The Journal of clinical endocrinology and metabolism.

[12]  G. Nepom,et al.  Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity , 2005 .

[13]  M. V. von Herrath.  E1-INT (Transition Therapeutics/Novo Nordisk). , 2005, Current opinion in investigational drugs.

[14]  M. Atkinson,et al.  Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes , 2004, Nature Reviews Immunology.

[15]  H. Mcdevitt,et al.  Specific antigen vaccination to treat autoimmune disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Bonifacio,et al.  Pancreatic β-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes , 2004 .

[17]  J. Habener,et al.  Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. , 2004, Diabetes.

[18]  Jeffrey A. Bluestone,et al.  In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes , 2004, The Journal of experimental medicine.

[19]  C. Ferran,et al.  DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY CURES NEW-ONSET DIABETES, PREVENTS RECURRENT AUTOIMMUNE DIABETES, AND DELAYS ALLOGRAFT REJECTION IN NONOBESE DIABETIC MICE1 , 2004, Transplantation.

[20]  E. Gale.  European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes , 2004, The Lancet.

[21]  S. Martin,et al.  Follow-up of cyclosporin A treatment in Type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects , 1991, Diabetologia.

[22]  E. Bonifacio,et al.  Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. , 2004, Diabetes care.

[23]  J. Miyazaki,et al.  Systemic Administration of IL-18 Promotes Diabetes Development in Young Nonobese Diabetic Mice , 2003, The Journal of Immunology.

[24]  M. Knip,et al.  Intranasally administered insulin intended for prevention of type 1 diabetes—a safety study in healthy adults , 2003, Diabetes/metabolism research and reviews.

[25]  J. Bluestone,et al.  TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes , 2003, Nature Medicine.

[26]  Li-he Guo,et al.  Intramuscular injection of interleukin-10 plasmid DNA prevented autoimmune diabetes in mice. , 2003, Acta pharmacologica Sinica.

[27]  I. Cohen,et al.  T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  J. Bluestone,et al.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala) , 2003 .

[29]  J. Bluestone,et al.  Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). , 2003, The Journal of clinical investigation.

[30]  P. Pozzilli.  The DPT‐1 trial: a negative result with lessons for future type 1 diabetes prevention , 2002, Diabetes/metabolism research and reviews.

[31]  D. Wegmann,et al.  Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. , 2002, Diabetes.

[32]  M. Herrath.  Vaccination to prevent type 1 diabetes. , 2002 .

[33]  M. V. von Herrath.  Vaccination to prevent type 1 diabetes , 2002, Expert review of vaccines.

[34]  S. Casares,et al.  Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide–MHC class II chimera , 2002, Nature Immunology.

[35]  L. Chatenoud,et al.  Nonmitogenic CD3 Antibody Reverses Virally Induced (Rat Insulin Promoter-Lymphocytic Choriomeningitis Virus) Autoimmune Diabetes Without Impeding Viral Clearance1 , 2002, The Journal of Immunology.

[36]  M. Seno,et al.  Promotion of β-Cell Regeneration by Betacellulin in Ninety Percent-Pancreatectomized Rats. , 2001, Endocrinology.

[37]  I. Cohen,et al.  β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial , 2001, The Lancet.

[38]  R. Flavell,et al.  A Dual Role for TNF-α in Type 1 Diabetes: Islet-Specific Expression Abrogates the Ongoing Autoimmune Process When Induced Late but Not Early During Pathogenesis1 , 2001, The Journal of Immunology.

[39]  I. Cohen,et al.  Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. , 2001, Lancet.

[40]  M. Seno,et al.  Promotion of beta-cell regeneration by betacellulin in ninety percent-pancreatectomized rats. , 2001, Endocrinology.

[41]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[42]  A. T. N. Group,et al.  No effect of oral insulin on residual beta-cell function in recent-onset Type I diabetes (the IMDIAB VII) , 2000, Diabetologia.

[43]  J. Petersen,et al.  Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. , 1999, Journal of immunology.

[44]  H. Kolb,et al.  IL-18 inhibits diabetes development in nonobese diabetic mice by counterregulation of Th1-dependent destructive insulitis. , 1999, Journal of immunology.

[45]  H. Kolb,et al.  The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. , 1998, Diabetes.

[46]  L. Chatenoud,et al.  Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  T. Maki,et al.  Long-term abrogation of autoimmune diabetes in nonobese diabetic mice by immunotherapy with anti-lymphocyte serum. , 1992, Proceedings of the National Academy of Sciences of the United States of America.